Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$81 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-3.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
36.2
Industry P/E
25.57
EV/EBITDA
-5.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
5,104,360
CFO
$-120.00 Mln
EBITDA
$-135.28 Mln
Net Profit
$-138.85 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eyenovia (EYEN)
| -39.4 | -31.8 | 532.1 | -92.9 | -62.7 | -52.1 | -- |
|
BSE Sensex*
| -12.0 | -9.7 | -12.2 | -1.2 | 8.7 | 8.4 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Eyenovia (EYEN)
| -92.8 | 27.6 | -59.3 | -34.0 | 35.3 | 57.2 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Eyenovia, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license... agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York. Read more
Co-Founder & Executive Chairman
Dr. Tsontcho Ianchulev M.D., M.P.H., MPH
Co-Founder & Executive Chairman
Dr. Tsontcho Ianchulev M.D., M.P.H., MPH
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Eyenovia Inc (EYEN) is $7.08 (NASDAQ) as of 01-Aug-2025 09:30 EDT. Eyenovia Inc (EYEN) has given a return of -62.66% in the last 3 years.
Since, TTM earnings of Eyenovia Inc (EYEN) is negative, P/E ratio is not available.
The P/B ratio of Eyenovia Inc (EYEN) is 36.17 times as on 01-Aug-2025, a 558 premium to its peers’ median range of 5.50 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of Eyenovia Inc (EYEN) are Rs 104.00 and Rs 0.85 as of 22-Mar-2026.
Eyenovia Inc (EYEN) has a market capitalisation of $ 81 Mln as on 01-Aug-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Eyenovia Inc (EYEN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-8.74
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.